Patents by Inventor Robert M. Kral, Jr.

Robert M. Kral, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING COVID-19 USING BARDOXOLONE METHYL OR ANALOGS THEREOF
    Publication number: 20230255982
    Abstract: The present invention provides methods of treating patients infected with a coronavirus. In particular, provided are methods of treating or preventing COVID-19, or symptoms or complications thereof, in patients in need thereof using bardoxolone methyl or analogs thereof, and/or preventing the onset of COVID-19 in patients infected with SARS-COV-2.
    Type: Application
    Filed: May 7, 2021
    Publication date: August 17, 2023
    Applicant: REATA PHARMACEUTICALS HOLDINGS, LLC
    Inventors: Deborah FERGUSON, W. Christian WIGLEY, Colin MEYER, J. Warren HUFF, Robert M. KRAL, Jr.
  • NATURAL PRODUCT ANALOGS INCLUDING AN ANTI-INFLAMMATORY CYANOENONE PHARMACORE AND METHODS OF USE
    Publication number: 20180237383
    Abstract: This invention provides novel compounds comprising the following anti-inflammatory pharmacore: wherein X, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: October 24, 2017
    Publication date: August 23, 2018
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Eric ANDERSON, Gary L. BOLTON, Deborah A. FERGUSON, Xin JIANG, Robert M. KRAL, JR., Patrick M. O'BRIEN, Melean VISNICK
  • Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use
    Patent number: 9796668
    Abstract: This invention provides novel compounds comprising the following anti-inflammatory pharmacore: wherein X, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: October 24, 2017
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Eric Anderson, Gary L. Bolton, Deborah A. Ferguson, Xin Jiang, Robert M. Kral, Jr., Patrick M. O'Brien, Melean Visnick
  • NATURAL PRODUCT ANALOGS INCLUDING AN ANTI-INFLAMMATORY CYANOENONE PHARMACORE AND METHODS OF USE
    Publication number: 20160145200
    Abstract: This invention provides novel compounds comprising the following anti-inflammatory pharmacore: wherein X, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: November 24, 2015
    Publication date: May 26, 2016
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Eric ANDERSON, Gary L. BOLTON, Deborah A. FERGUSON, Xin JIANG, Robert M. KRAL, JR., Patrick M. O'BRIEN, Melean VISNICK
  • Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use
    Patent number: 9233998
    Abstract: This invention provides novel compounds comprising the following anti-inflammatory pharmacore: wherein X, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: January 12, 2016
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Eric Anderson, Gary L. Bolton, Deborah A. Ferguson, Xin Jiang, Robert M. Kral, Jr., Patrick M. O'Brien, Melean Visnick
  • Betulinic acid derivatives and methods of use thereof
    Patent number: 8778990
    Abstract: This invention features betulinic acid derivatives having the formula: wherein the variables are defined herein. The invention also provides related compounds and intermediates thereof, as well as pharmaceutical compositions, kits, and articles of manufacture comprising such compounds. Treatment methods and methods of manufacture are also provided.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: July 15, 2014
    Assignees: Trustees of Dartmouth College, Reata Pharmaceuticals, Inc.
    Inventors: Tadashi Honda, Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Robert M. Kral, Jr., Melean Visnick
  • Forms of CDDO methyl ester
    Patent number: 8633243
    Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: January 21, 2014
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, Jr.
  • NOVEL FORMS OF CDDO METHYL ESTER
    Publication number: 20120330050
    Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.
    Type: Application
    Filed: June 29, 2012
    Publication date: December 27, 2012
    Inventors: John WALLING, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, JR.
  • Forms of CDDO methyl ester
    Patent number: 8309601
    Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: November 13, 2012
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, Jr.
  • COMPOUNDS INCLUDING AN ANTI-INFLAMMATORY PHARMACORE AND METHODS OF USE
    Publication number: 20120283450
    Abstract: This invention provides novel compounds comprising the following anti-inflammatory pharmacore: wherein X, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: July 18, 2012
    Publication date: November 8, 2012
    Inventors: Eric Anderson, Gary L. Bolton, Deborah A. Ferguson, Xin Jiang, Robert M. Kral, JR., Patrick M. O'Brien, Melean Visnick
  • Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use
    Patent number: 8258329
    Abstract: This invention provides novel compounds comprising the following anti-inflammatory pharmacore: wherein X, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: April 20, 2009
    Date of Patent: September 4, 2012
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: Eric Anderson, Gary L. Bolton, Deborah A. Ferguson, Xin Jiang, Robert M. Kral, Jr., Patrick M. O'Brien, Melean Visnick
  • Betulinic Acid Derivatives and Methods of Use Thereof
    Publication number: 20120101149
    Abstract: This invention features betulinic acid derivatives having the formula: wherein the variables are defined herein. The invention also provides related compounds and intermediates thereof, as well as pharmaceutical compositions, kits, and articles of manufacture comprising such compounds. Treatment methods and methods of manufacture are also provided.
    Type: Application
    Filed: October 29, 2009
    Publication date: April 26, 2012
    Inventors: Tadashi Honda, Michael B. Sporn, Karen T. Liby, Gordon W. Gribble, Robert M. Kral, JR., Melean Visnick
  • NOVEL FORMS OF CDDO METHYL ESTER
    Publication number: 20120071684
    Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.
    Type: Application
    Filed: November 29, 2011
    Publication date: March 22, 2012
    Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, JR.
  • Forms of CDDO methyl ester
    Patent number: 8088824
    Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.
    Type: Grant
    Filed: August 13, 2008
    Date of Patent: January 3, 2012
    Assignee: Reata Pharmaceuticals Inc.
    Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, Jr.
  • COMPOUNDS INCLUDING AN ANTI-INFLAMMATORY PHARMACORE AND METHODS OF USE
    Publication number: 20100048887
    Abstract: This invention provides novel compounds comprising the following anti-inflammatory pharmacore: wherein X, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: April 20, 2009
    Publication date: February 25, 2010
    Inventors: Eric Anderson, Gary L. Bolton, Deborah A. Ferguson, Xin Jiang, Robert M. Kral, JR., Patrick M. O'Brien, Melean Visnick
  • COMBINATION THERAPY WITH SYNTHETIC TRITERPENOIDS AND GEMCITABINE
    Publication number: 20090048205
    Abstract: The present invention concerns methods for treating cancer, such as pancreatic cancer, using combination therapies, including the combination of a synthetic triterpenoid, e.g., CDDO-Me, and gemcitabine.
    Type: Application
    Filed: August 15, 2008
    Publication date: February 19, 2009
    Inventors: Colin Meyer, Michael Andreeff, Marina Konopleva, Robert M. Kral, JR.
  • NOVEL FORMS OF CDDO METHYL ESTER
    Publication number: 20090048204
    Abstract: A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.
    Type: Application
    Filed: August 13, 2008
    Publication date: February 19, 2009
    Inventors: John Walling, Stephan D. Parent, David T. Jonaitis, Robert M. Kral, JR.
  • 16 KDA insecticidal toxin from bracons hebetor, nucleic acids encoding said toxin, and methods of use
    Patent number: 6156539
    Abstract: This invention relates to the purification of a group of insecticidally effective toxins isolated from the wasp, Bracon hebetor, characterized by their neurotoxic effect on insect pest and low mammalian toxicity. The cDNA sequences for two of these toxins have been isolated, and the complete coding sequence is provided. This invention also discloses methods for producing recombinant toxins, as well as methods of utilizing these toxins as insecticidal agents.
    Type: Grant
    Filed: February 22, 1999
    Date of Patent: December 5, 2000
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Janice H. Johnson, Robert M. Kral, Jr., Karen Krapcho
  • Insecticidal toxins from Bracon hebetor nucleic acid encoding said toxin and methods of use
    Patent number: 5874298
    Abstract: This invention relates to the purification of a group of insecticidally effective toxins isolated from the wasp, Bracon hebetor, characterized by their neurotoxic effect on insect pest and low mammalian toxicity. The cDNA sequences for two of these toxins have been isolated, and the complete coding sequence is provided. This invention also discloses methods for producing recombinant toxins, as well as methods of utilizing these toxins as insecticidal agents.
    Type: Grant
    Filed: February 17, 1995
    Date of Patent: February 23, 1999
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Janice H. Johnson, Robert M. Kral, Jr., Karen Krapcho
  • Insecticidal peptides from spider venom
    Patent number: 5688764
    Abstract: This invention relates to the purification of a family of insecticidally effective peptides isolated from the spider, Calisoga sp., characterized by their neurotoxic effect on insect pest and low mammalian toxicity. The cDNA sequences for three of these peptides have been isolated, and the complete coding sequence is provided. This invention also discloses methods for producing recombinant peptides, as well as methods of utilizing these peptides as insecticidal agents.
    Type: Grant
    Filed: February 17, 1995
    Date of Patent: November 18, 1997
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: Janice H. Johnson, Robert M. Kral, Jr., Karen Krapcho